We are live on ! Find out more
PBM

Propel Bio Management Portfolio holdings

AUM $191M
1-Year Est. Return 102.42%
This Fund
S&P 500
This Quarter Est. Return
+17.45%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$99.9M
AUM Growth
+$17.5M
Cap. Flow
+$8.31M
Cap. Flow %
8.32%
Top 10 Hldgs %
87.06%
Holding
21
New
5
Increased
2
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$5.86M
2
CLDX icon
Celldex Therapeutics
CLDX
+$3.59M
3
JSPR icon
Jasper Therapeutics
JSPR
+$3.12M
4
DCTH icon
Delcath Systems
DCTH
+$2.37M
5
CMPS
Compass Pathways
CMPS
+$2.29M

Top Sells

Rank Stock Value
1
ACHV icon
Achieve Life Sciences
ACHV
+$6.5M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.82M
3
CAPR icon
Capricor Therapeutics
CAPR
+$695K
4
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$423K
5
TCRX icon
TScan Therapeutics
TCRX
+$274K

Sector Composition

Rank Sector Weight
1 Healthcare 76.77%
2 Energy 23.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PAGP icon
1
Plains GP Holdings
PAGP
$5.54B
$23.2M 23.23%
1,272,360
– –
ACHV icon
2
Achieve Life Sciences
ACHV
$834M
$11.9M 11.94%
3,786,425
-2,366,666
-38% -$6.5M
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$10.9M 10.88%
228,884
– –
MIST icon
4
Milestone Pharmaceuticals
MIST
$144M
$10.2M 10.26%
5,124,890
+3,333,333
+186% +$5.86M
APLT
5
DELISTED
Applied Therapeutics
APLT
$6.83M 6.83%
11,285,420
– –
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$743M
$6.51M 6.51%
552,927
-370,000
-40% -$3.82M
ABEO icon
7
Abeona Therapeutics
ABEO
$339M
$5.14M 5.15%
974,022
– –
DCTH icon
8
Delcath Systems
DCTH
$567M
$4.71M 4.72%
438,509
+212,457
+94% +$2.37M
CLDX icon
9
Celldex Therapeutics
CLDX
$3.07B
$4.01M 4.01%
+155,000
New +$3.59M
TCRX icon
10
TScan Therapeutics
TCRX
$51.1M
$3.52M 3.52%
1,932,304
-154,835
-7% -$274K
CMPS
11
Compass Pathways
CMPS
$1.9B
$2.92M 2.93%
+510,000
New +$2.29M
NKTR icon
12
Nektar Therapeutics
NKTR
$2.48B
$2.79M 2.79%
+49,000
New +$1.62M
JSPR icon
13
Jasper Therapeutics
JSPR
$23.3M
$2.45M 2.45%
+1,028,806
New +$3.12M
ZVRA icon
14
Zevra Therapeutics
ZVRA
$686M
$2.21M 2.21%
231,874
– –
VRDN icon
15
Viridian Therapeutics
VRDN
$2.61B
$1.94M 1.94%
+90,000
New +$1.62M
LONA
16
LeonaBio Inc
LONA
$74.8M
$618K 0.62%
149,279
– –
CAPR icon
17
Capricor Therapeutics
CAPR
$558M
– –
-70,000
Closed -$695K
EIGR
18
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-146,381
Closed -$423K

Similar funds

CFG
Capital Financial Group Greenwood Village, Colorado $191M AUM
MWM
Magnolia Wealth Management Dothan, Alabama $191M AUM 17.58% 1-Year Est. Return
ALWM
Andrews Lucia Wealth Management Danville, California $191M AUM 24.94% 1-Year Est. Return
PFA
Pillar Financial Advisors Louisville, Kentucky $191M AUM 21.21% 1-Year Est. Return
LKWM
Lee-Kelleher Wealth Management Fulton, Maryland $191M AUM 28.48% 1-Year Est. Return
NWM
Navigoe Wealth Management Redondo Beach, California $191M AUM 25.21% 1-Year Est. Return
AA
Atmos Advisory Pittsburgh, Pennsylvania $191M AUM 12.84% 1-Year Est. Return
MCA
Martin Capital Advisors San Antonio, Texas $191M AUM 42.42% 1-Year Est. Return

Propel Bio Management's Q3 2025 Portfolio in Review

As of Q3 2025, Propel Bio Management held 21 positions worth $99.9M, up 21% from $82.4M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Propel Bio Management deployed $8.31M of net new capital in Q3 2025, opening 5 new positions and adding to 2 existing holdings. Its largest new stake was Celldex Therapeutics: 155,000 shares worth $4.01M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 69% a quarter earlier, followed by Energy.

On the sell side, the largest reduction was Achieve Life Sciences, an estimated $6.5M trimmed.

  • Propel Bio Management's largest Q3 2025 buy was Celldex Therapeutics: 155,000 shares worth $4.01M.
  • Propel Bio Management added most to Milestone Pharmaceuticals in Q3 2025, an estimated $5.86M increase.
  • Propel Bio Management's biggest Q3 2025 reduction was Achieve Life Sciences, cutting an estimated $6.5M.
  • Propel Bio Management fully exited Capricor Therapeutics in Q3 2025, selling an estimated $695K.
  • Propel Bio Management's ten largest holdings make up 87% of its $99.9M portfolio in Q3 2025.
  • Propel Bio Management opened 5 new positions and closed 5 in Q3 2025.
  • Propel Bio Management's portfolio value rose 21% quarter-over-quarter to $99.9M.

Based on Propel Bio Management's 13F filing for Q3 2025, filed 12 Nov 2025.